Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders

Douglas F. Lake, Alexa J. Roeder, Maria J. Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky
doi: https://doi.org/10.1101/2021.11.30.21266716
Douglas F. Lake
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: douglas.lake@asu.edu
Alexa J. Roeder
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria J. Gonzalez-Moa
2AXIM Biotech, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Koehler
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Kaleta
3Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paniz Jasbi
4Arizona State University, College of Health Solutions, Phoenix, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Vanderhoof
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davis McKechnie
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Forman
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baylee Edwards
1Arizona State University, School of Life Sciences, Tempe, AZ USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alim Seit-Nebi
2AXIM Biotech, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergei Svarovsky
2AXIM Biotech, San Diego, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To determine if poor responders to COVID-19 RNA vaccines (<50% neutralisation) after two doses would remain poor responders, or if a third dose could elicit high levels of NAbs.

Design Clinical follow-up study

Setting Academic and medical institutions in USA

Participants 269 healthy individuals ranging in age from 19 to 80 (Average age = 51; 165 females and 104 males) who received either BNT162b2 (Pfizer) or mRNA1273 (Moderna) vaccines.

Main Outcome Measures NAb levels were measured: i) 2-4 weeks after a second vaccine dose, ii) 2-4 months after the second dose, iii) within 1-2 weeks prior to a third dose and iv) 2-4 weeks after a third RNA vaccine dose.

Results In 269 study participants, percent neutralisation ranged from 0% to 99% 2-4 weeks after a second vaccine dose. The majority of vaccine recipients (154/269, 57%) demonstrated NAb levels at ≥75% 2-4 weeks after their second dose. Our study also revealed that 25% of vaccine recipients did not neutralise above 50% (Median neutralisation = 21%, titers <1:80) within a month after their second dose. We called these individuals “vaccine poor responders” (VPRs). Twenty-three VPRs ranging in age from 31 to 79 (10 males, 13 females, average age = 62.5) independently obtained a third dose of either BNT162b2 or mRNA-1273 vaccine 1-8 months (average = 5 months) after their second dose. Within a month after their third dose, poor responders showed an average 20-fold increase in NAb levels (range 46%-99%).

Conclusions The results suggest that poor responders are not permanently poor responders; they can generate high NAb levels with an additional vaccine dose–independent of mRNA vaccine manufacturer. Previous reports indicate that NAb levels decline much more rapidly than clinical protection from hospitalisation and disease, but that does not account for vaccine recipients who never generated high levels of NAbs after two doses. It is possible that poor responders are a source of breakthrough infections. Although it is not known what levels of NAbs protect from infection or disease, many vaccine recipients in high-risk professions may wish to keep peripheral NAb levels high, limiting infection, asymptomatic viral replication, and potential transmission.

Competing Interest Statement

DFL and SS are co-founders of Sapphire, the research division of AXIM Biotechnologies. SS, MGM, and AS-N are employed by AXIM. All other authors have no competing interests

Funding Statement

This study was partially funded by Axim Biotech, San Diego, CA

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Arizona State University Internal Review Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Co-first authors

  • Copyright Statement: “the Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.”

Data Availability

All de-identified raw data corresponding to results shown as part of the study demonstrated in this manuscript can be made available upon request to corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 02, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
Douglas F. Lake, Alexa J. Roeder, Maria J. Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2021.11.30.21266716; doi: https://doi.org/10.1101/2021.11.30.21266716
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
Douglas F. Lake, Alexa J. Roeder, Maria J. Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2021.11.30.21266716; doi: https://doi.org/10.1101/2021.11.30.21266716

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10770)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (741)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12495)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5336)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)